Satellos Bioscience (MSCL) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on developing oral small molecule therapies for degenerative muscle diseases, with lead candidate SAT-3247 targeting Duchenne muscular dystrophy (DMD).

• Proprietary MyoReGenX™ platform enables discovery of drugs that restore muscle stem cell polarity and regeneration.

• Pipeline includes follow-on programs for other muscular dystrophies and muscle degeneration indications.

Financial performance and metrics

• Reported net loss of $28.1 million for the year ended December 31, 2024, compared to $15.9 million in 2023, driven by increased R&D and clinical trial costs.

• Cash and cash equivalents plus short-term investments totaled $69.9 million as of December 31, 2024, sufficient to fund operations through 2026.

• No revenue generated to date; company remains in development stage and expects continued operating losses.

Use of proceeds and capital allocation

• December 2024 equity offering raised gross proceeds of $56.96 million, with net proceeds allocated primarily to Phase 2 clinical development of SAT-3247 and supporting activities.

• Remaining proceeds earmarked for general corporate and administrative expenses.

• May 2023 equity offering proceeds were used for CMC, IND-enabling studies, Phase 1 clinical trials, and discovery research.